Treatments

FDA Authorizes Fourth Monoclonal Antibody Drug

Last Friday, the FDA authorized emergency use of Eli Lilly’s monoclonal antibody treatment, bebtelovimab, for treating mild-to-moderate COVID-19. Bebtelovimab has been shown to be highly effective against the Omicron variant, and is the fourth treatment made available for high-risk COVID patients. It has not been proven whether bebtelovimab can prevent severe disease, but trial data suggest that bebtelovimab may reduce viral replication when taken within 7 days upon onset of COVID-19 symptoms.

Read More »

FDA Expands Authorization Around Remdesivir to Treat COVID-19

On January 21, the FDA expanded the use of remdesivir to non-hospitalized adults and children who have mild-to-moderate COVID-19, who are at risk of severe disease. Previously, remdesivir was only available to hospitalized patients. This decision was based on a clinical trial including 562 participants with mild-to-moderate COVID-19, who had displayed symptoms within the previous 7 days and had at least one risk factor for severe disease.

Read More »

Two COVID-19 Antiviral Pills Granted EUA

This week, the FDA granted EUA for two COVID-19 oral antiviral pills, which will be added as a second treatment protocol for COVID-19. Up until now, monoclonal antibodies have been the only authorized treatment for patients with COVID-19.

Read More »